BioCentury
ARTICLE | Clinical News

Glepaglutide: Completed Ph II enrollment

February 16, 2017 8:13 PM UTC

Zealand completed enrollment of about 18 patients in a double-blind, crossover, Danish Phase II trial evaluating 3 dose levels of subcutaneous glepaglutide given by an injectable pen device in 3-week ...

BCIQ Company Profiles

Zealand Pharma A/S